The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of sunitinib in renal cell cancer with untreated brain metastases.
C. Chevreau
Honoraria - Bayer; Novartis; Wyeth
Research Funding - Pfizer
A. Ravaud
No relevant relationships to disclose
B. Escudier
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche
A. Caty
No relevant relationships to disclose
R. Delva
No relevant relationships to disclose
F. Rolland
No relevant relationships to disclose
S. Oudard
No relevant relationships to disclose
R. Herve
No relevant relationships to disclose
E. Blanc
No relevant relationships to disclose
C. Ferlay
No relevant relationships to disclose
N. Lignon
No relevant relationships to disclose
S. Negrier
Honoraria - GlaxoSmithKline; Novartis; Pfizer; Roche
Research Funding - GlaxoSmithKline; Pfizer; Roche